Forget Aurora Cannabis (TSX:ACB): Buy This Pure Extraction Company Instead!

Shares in Medipharm Labs Corp (TSXV:LABS) are up more than 213% so far in 2019. Find out what makes this company such a unique and interesting investment opportunity.

| More on:

For Canada’s second-largest licensed cannabis producer Aurora Cannabis, it hasn’t exactly been such a “hot” summer.

In fact, shares in ACB are down close to -40% since the middle of March, outpacing the losses of the broader cannabis sector as represented by the HORIZONS MARIJUANA ETF, which is also down by about -30% over the same period.

However, in the case of pure cannabis extraction company Medipharm Labs (TSXV:LABS), it’s actually been a much different story.

Stock in LABS is up an amazing 213% so far in 2019, and despite selling off some of those gains since May, Medipharm shares have begun to resume some of their momentum as of late, up more than 36% just in last week’s trading alone.

But more than simply trying to chase the latest wave of momentum, there are several reasons why I happen to like Medipharm a lot as an investment these days.

The company is going after the high-growth, high-margin cannabis derivatives segment

Now, in case you’re thinking that cannabis derivatives stand to represent complex and exotic financially engineered cannabis investments, it actually doesn’t.

Cannabis derivatives refers to the incorporation of the traditional cannabis flower into new alternative applications for the drug such as vapes, oils, capsules, topical creams, and, possibly even some time later this year, edibles.

What’s really interesting about the cannabis derivatives market right now is that it’s beginning to look more and more as though this is where the real growth and innovation in the cannabis industry is likeliest to come from.

Not only do derivative applications allow consumers a wider variety of avenues to choose from when dosing their cannabis, but they also tend to involve a more complex manufacturing process, which, in turn, represents more value (and potential for profits) through each stage of the supply chain.

It’s a unique opportunity that not only stands to represent a “win” for cannabis shoppers but also retailers, wholesalers, and, of course, extraction companies like LABS.

A two-pronged business model

LABS is basically running two separate businesses.

One is set up as a wholesaling operation whereby licensed producers (LPs) sell their dried flower inventory to the company, which processes it and then sells it to other LPs to use in applications like vapes, oils, edibles, etc.

The second is essentially a tolling agreement whereby LPs pay LABS to process their dry product and returning it to them for a fee.

Certain derivatives products are outpacing the growth of the broader cannabis markets

In its most recent presentation to investors, the company presented research compiled by New Frontier Data and MJ Freeway Retail Data Webinar to suggest that growth in the cannabis concentrates market has grown by 100% over the past three years and now accounts for 33% of total industry sales.

Within that market, the research suggests that vape pens represent the largest potential for growth because of their faster onset times and ability to provide users with more accurate dosing.

Foolish bottom line

It’s not been any real secret among industry insiders that as the market for cannabis investments continues to mature, investors will need to seek out less-conventional avenues to gain exposure to what’s expected to be a 20% compound annual growth for the industry.

LABS certainly appears to represent one of those types of investments.

With the recent completion of its first shipment to the Australian market, the company has the momentum going in its favour.

And now with its share price beginning to follow suit, it could be a good time for investors to jump on board.

Making the world smarter, happier, and richer.

Should you invest $1,000 in Enbridge right now?

Before you buy stock in Enbridge, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Enbridge wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $21,345.77!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 24 percentage points since 2013*.

See the Top Stocks * Returns as of 4/21/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jason Phillips has no position in any of the stocks mentioned.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

Buy the Dip Before It’s Too Late: This Canadian Stock Won’t Stay Cheap Forever

Investors might think that cannabis stocks are out, but this one could be the top Canadian stock to consider.

Read more »

a person watches a downward arrow crash through the floor
Stocks for Beginners

Plummet Alert: Is This TSX Growth Stock a Bargain or a Falling Knife?

This growth stock was once a major winner, but can investors wait for more?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

What to Know About Canadian Cannabis Stocks for 2025

Let's dive into two top Canadian cannabis stocks and where they may be headed from here (given the recent moves…

Read more »

Researcher works in hemp field
Cannabis Stocks

Aurora Cannabis Stock Is up 46% in 2025: Are Investors Going From 5 Years of Pain to a 2025 Gain?

Shares of Aurora Cannabis have staged a comeback in 2025, outpacing the broader markets comfortably. Is ACB stock a good…

Read more »

A plant grows from coins.
Stocks for Beginners

3 Growth Stocks That Could Skyrocket in 2025 and Beyond

It could be a big year for these sectors, and these growth stocks in particular throughout 2025.

Read more »

money goes up and down in balance
Tech Stocks

2 TSX Stocks to Buy and 2 to Avoid in the Looming Trade War

The looming U.S.-Canada trade war has changed the business environment. Here are some TSX stocks to buy and avoid in…

Read more »

space ship model takes off
Cannabis Stocks

2 Canadian Stocks With Strong Momentum for 2025

Celestica Inc. (TSX:CLS) stock and Dollarama (TSX:DOL) stock have sustained strong price growth momentum for a long time.  Here’s why…

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Pot Stocks: Buy, Sell, or Hold in 2025?

Cannabis stocks remain a bit risky, but could long-term investors be in for more pain or far more profits?

Read more »